Sam Truex focuses on building companies that translate groundbreaking science into innovative medicines for underserved patients.
Sam has contributed to building multiple companies in the Atlas portfolio, serving as chief business officer at Padlock Therapeutics, chief operating officer at Synlogic (NASDAQ: SYBX) and, most recently as chief executive officer of Quench Bio. Sam serves as an independent board member at HotSpot Therapeutics and has consulted at various times for Disc Medicine, Ikena Oncology (NASDAQ: IKNA), Kymera Therapeutics (NASDAQ: KYMR), and Obsidian Therapeutics. Earlier in her career, Sam served as VP of corporate development at Biogen, leading multiple drug programs from preclinical to commercial launch stages and leading several transactions. Prior to Biogen, Sam worked for Genzyme, Chiron, and Health Advances.
Sam is active in giving back to the community via her creation of the Teton Biotech Mini-Internship, a primer on biotech careers for college students. She also serves as chair of the board of Thayer School of Engineering at Dartmouth College and is a member of the board of Life Science Cares, which brings together the volunteer and philanthropic resources of our industry to address the impact of poverty in our community. Sam earned a AB in biology from Dartmouth College, a BE in biomedical engineering from Thayer School at Dartmouth College, and a MBA at the Tuck School of Business at Dartmouth College.
Sam enjoys hiking and all forms of skiing. She aims to complete all of New Hampshire’s 4000+ foot peaks by 2022.